Treating HER2-mutant advanced biliary tract cancer with neratinib

Bookmark and Share
Published: 15 Jul 2019
Views: 768
Rating:
Save
Dr James Harding - Memorial Sloan kettering Cancer Center, New York, USA

Dr James Harding speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the phase II findings of the SUMMIT trial, reporting the trial has found clinical benefits in using neratinib to treat HER2-mutant advanced biliary tract cancer patients.

He explains that there is a great interest in using precision medicine to find therapeutic targets in biliary tract cancers, and comments on the need for genotyping to become faster, cheaper and more efficient so that this kind of treatment can become more accessible.

Dr Harding concludes by outlining the next steps of the study.